Approved indications: Orlistat is FDA-approved as an adjunct to a reduced-calorie diet for obesity management, including weight loss, weight maintenance, and reduction of weight regain in people with obesity (BMI ≥30 kg/m²) or BMI ≥27 kg/m² with risk factors such as hypertension, diabetes, or dyslipidemia; the 60 mg over-the-counter product is approved for weight loss in overweight adults (BMI ≥25) who are 18 years or older following a low-fat, reduced-calorie diet.

Off-label uses: Clinicians may occasionally use orlistat off-label for conditions linked to excess weight, such as reducing progression from impaired glucose tolerance to type 2 diabetes or helping manage fatty liver disease or polycystic ovary syndrome, but the supporting evidence is modest and lifestyle measures remain the main treatment.

Efficacy expectations: Most weight loss occurs in the first 3–6 months; on average, orlistat adds about 3–5% of initial body weight (roughly 3–4 kg) more loss over one year than diet alone, and more patients achieve clinically meaningful losses of at least 5–10% of body weight.

Metabolic benefits and durability: In people who respond, treatment can modestly improve blood pressure, cholesterol, and progression from prediabetes to diabetes, and helps some patients regain less weight after prior loss, although the degree of benefit varies and weight often partially returns when the drug is stopped.

Comparison to other weight-loss drugs: Orlistat produces less average weight loss than modern GLP-1–based agents (such as semaglutide or tirzepatide) but has a long safety track record, is available orally including over the counter, and mainly causes local gastrointestinal side effects rather than systemic cardiovascular or psychiatric effects.

Typical dosing: For prescription orlistat (Xenical), the usual adult and adolescent (≥12 years) dose is 120 mg by mouth three times daily with each main meal containing fat, for a maximum of 360 mg per day; for over-the-counter orlistat (Alli), adults 18 years and older typically take 60 mg with each fat-containing meal up to three times daily (maximum 180 mg per day).

How to take it: Take each capsule during the meal or within 1 hour after starting a meal that contains some fat, with a glass of water; skip the dose if you miss a meal or if the meal contains no fat, and do not take extra capsules to make up for a missed dose.

Diet and supplements: Orlistat should always be used with a reduced-calorie diet in which about 30% of total calories come from fat, with fat spread evenly across three main meals to limit gastrointestinal side effects; a daily multivitamin containing vitamins A, D, E, K, and beta-carotene should be taken at least 2 hours apart from orlistat (often at bedtime).

Special dosing instructions: No routine dose adjustment is required solely for older adults, mild to moderate kidney disease, or liver impairment, but closer monitoring is recommended in people with kidney problems, and orlistat should not be used in patients with chronic malabsorption or cholestasis; avoid combining orlistat with other prescription weight-loss medicines unless directed by a specialist.

Missed dose guidance: If you forget a dose but remember within 1 hour of eating a fat-containing meal, you may take it when you remember; if more than 1 hour has passed or the meal was skipped or fat-free, skip the missed dose and resume your usual schedule at the next appropriate meal without doubling up.

Overdose: Accidental extra doses most often cause more intense gastrointestinal symptoms such as diarrhea, oily stools, or abdominal pain; there is no specific antidote, so supportive care is used, and anyone with a suspected significant overdose should contact a healthcare professional, poison control center, or emergency services, especially if they have underlying liver or kidney disease or worrisome symptoms.

Common side effects: Because orlistat blocks fat absorption, the most frequent effects are gastrointestinal and include oily or fatty stools, oily spotting on underwear, gas with oily discharge, urgent or more frequent bowel movements, loose stools, and abdominal discomfort, which tend to start soon after beginning treatment, are more likely with high-fat meals, and often improve over time if total fat intake is kept to about 30% of calories.

Nutrient effects: Orlistat can reduce absorption of fat-soluble vitamins (A, D, E, K) and beta-carotene, so patients are usually advised to take a daily multivitamin containing these nutrients at least 2 hours before or after a dose (often at bedtime) to reduce the risk of deficiencies.

Serious or rare adverse effects: Rare cases of severe liver injury (including liver failure) have been reported; warning signs include itching, loss of appetite, yellowing of the skin or eyes, dark urine, or pale stools and require prompt medical evaluation and stopping the drug.

Some patients have developed oxalate kidney stones or oxalate nephropathy with kidney injury, particularly those with prior kidney disease or risk factors; symptoms can include flank pain, blood in the urine, or reduced urine output, and kidney function should be monitored in at-risk patients.

Warnings and precautions: Orlistat is contraindicated in pregnancy, in people with chronic malabsorption syndromes, cholestasis, or known hypersensitivity to the drug, and over-the-counter formulations should not be used in anyone under 18 years; prescription use is generally limited to patients 12 years and older and is not recommended in younger children.

Caution is advised in people with significant kidney disease, a history of oxalate kidney stones, liver disease, gallbladder disease or gallstones, pancreatitis, eating disorders, or those taking certain interacting medications such as cyclosporine, levothyroxine, warfarin, some antiarrhythmics, antiepileptics, or antiretrovirals.

Comparative safety: Because orlistat is minimally absorbed into the bloodstream and acts mainly in the gut, it has fewer systemic stimulant, cardiovascular, or psychiatric effects than older appetite-suppressant drugs, but gastrointestinal symptoms, vitamin deficiencies, and rare liver or kidney problems are important safety considerations.

Reporting and staying informed: Patients should report bothersome or serious side effects to their prescriber and can submit reports directly to the FDA MedWatch program; up-to-date safety communications and label changes for orlistat (Xenical and Alli) are available on the FDA's drug safety webpages.

Major drug interactions: Orlistat can reduce absorption or alter effects of certain medicines; important interactions include cyclosporine and other transplant immunosuppressants (reduced drug levels and risk of rejection), levothyroxine (reduced absorption and possible hypothyroidism), warfarin and other oral anticoagulants (vitamin K reduction and increased INR), amiodarone (lower blood levels), antiepileptic drugs such as valproate or lamotrigine (reports of more seizures), and antiretroviral HIV medicines (reports of loss of virologic control).

Managing interactions: If orlistat is prescribed with cyclosporine, cyclosporine is usually taken at least 3 hours before or after orlistat with close level monitoring, and levothyroxine should be taken at least 4 hours apart with periodic thyroid function tests; patients on warfarin or similar anticoagulants need closer INR monitoring and possible dose adjustment, and those on antiepileptics, amiodarone, or antiretrovirals should be monitored for reduced drug effect or changes in seizure control or viral load.

Vitamins and supplements: Because orlistat decreases absorption of fat-soluble vitamins and beta-carotene, all users should take a daily multivitamin at a different time of day (at least 2 hours apart); high-dose fat-soluble vitamin or herbal fat-burning supplements should be used cautiously and spaced away from orlistat to avoid malabsorption or unpredictable effects.

Food, alcohol, and diagnostics: High-fat meals increase both the amount of blocked fat and the chance of bothersome gastrointestinal side effects, so a low-fat diet is essential; alcohol does not have a direct pharmacologic interaction but adds calories and can blunt weight loss, and orlistat does not usually interfere with standard imaging or lab tests beyond potential changes in vitamin levels and clotting tests.

Key precautions and who should avoid it: Orlistat should not be used in people with chronic malabsorption syndromes, cholestasis, known hypersensitivity to the drug, pregnancy, or in children under 12 years (and over-the-counter versions should not be used under age 18); caution is warranted in patients with kidney disease or a history of oxalate kidney stones, liver disease, gallbladder disease or gallstones, pancreatitis, eating disorders, or those taking multiple interacting drugs.

Monitoring needs: During treatment, clinicians typically monitor body weight, BMI, blood pressure, and lipid profile; consider periodic checks of fat-soluble vitamin status and nutritional markers in long-term users, renal function in those at risk of oxalate nephropathy, liver tests if symptoms of liver injury occur, INR in patients on warfarin, thyroid function in those on levothyroxine, cyclosporine levels in transplant recipients, and HIV viral load in patients on antiretrovirals.

Q: How much weight can I realistically expect to lose with orlistat?
A: When combined with a reduced-calorie, low-fat diet and regular physical activity, many people lose an additional 3–5% of their starting weight (a few extra kilograms or several pounds) over 6–12 months compared with diet alone, though results vary and some people lose more or less.

Q: How soon will I notice results after starting orlistat?
A: The medicine begins blocking fat absorption within a day or two, but visible weight changes usually appear over several weeks; if you have not lost around 5% of your initial body weight after about 3 months of regular use and good adherence to diet, your clinician may reassess whether to continue.

Q: What happens if I eat a very high-fat meal while taking orlistat?
A: Eating more fat than recommended (generally more than about 15 grams per meal or 30% of calories) greatly increases the chance of oily stools, gas with discharge, and urgent or even hard-to-control bowel movements, so keeping each meal modest in fat is important for comfort.

Q: Do I need to take a vitamin supplement while on orlistat?
A: Yes, most people are advised to take a daily multivitamin that contains vitamins A, D, E, K, and beta-carotene at bedtime or at least 2 hours before or after an orlistat dose, because the drug can reduce absorption of these fat-soluble vitamins.

Q: Can I use orlistat if I am pregnant, breastfeeding, or under 18 years old?
A: Orlistat should not be used during pregnancy, and is generally avoided while breastfeeding because it is unknown if it passes into breast milk and weight loss is not recommended; over-the-counter orlistat is for adults 18 and older, and prescription orlistat is only used in carefully selected adolescents 12 years and older under close medical supervision.

Storage: Store orlistat capsules at room temperature (about 68–77°F or 20–25°C), in a dry place away from excess heat, moisture, and direct light, and keep them in the original tightly closed container and out of the reach of children and pets.

Disposal: When capsules are expired or no longer needed, do not flush them in the toilet; use a community drug take-back program if available, or mix the capsules (out of their shells) with an undesirable substance such as used coffee grounds or cat litter, seal in a bag or container, and place in the household trash according to local regulations.